Rani Therapeutics RANI Stock
Rani Therapeutics Price Chart
Rani Therapeutics RANI Financial and Trading Overview
| Rani Therapeutics stock price | 1.48 USD |
| Previous Close | 0.55 USD |
| Open | 0.55 USD |
| Bid | 0.5 USD x 100 |
| Ask | 0.56 USD x 100 |
| Day's Range | 0.53 - 0.58 USD |
| 52 Week Range | 0.39 - 3.75 USD |
| Volume | 754.18K USD |
| Avg. Volume | 1.93M USD |
| Market Cap | 36.68M USD |
| Beta (5Y Monthly) | -0.014 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.77 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.75 USD |
RANI Valuation Measures
| Enterprise Value | 25.42M USD |
| Trailing P/E | N/A |
| Forward P/E | -0.5277228 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 30.569014 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 21.18 |
| Enterprise Value/EBITDA | -0.546 |
Trading Information
Rani Therapeutics Stock Price History
| Beta (5Y Monthly) | -0.014 |
| 52-Week Change | -76.41% |
| S&P500 52-Week Change | 18.63% |
| 52 Week High | 3.75 USD |
| 52 Week Low | 0.39 USD |
| 50-Day Moving Average | 0.53 USD |
| 200-Day Moving Average | 1.29 USD |
RANI Share Statistics
| Avg. Volume (3 month) | 1.93M USD |
| Avg. Daily Volume (10-Days) | 753.36K USD |
| Shares Outstanding | 43.59M |
| Float | 23M |
| Short Ratio | 1.78 |
| % Held by Insiders | 21.48% |
| % Held by Institutions | 11.17% |
| Shares Short | 7.13M |
| Short % of Float | 23.91% |
| Short % of Shares Outstanding | 18.17% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2024 |
| Most Recent Quarter (mrq) | March 31, 2025 |
| Next Fiscal Year End | December 31, 2025 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -6984.30% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -76.60% |
| Return on Equity (ttm) | -1187.52% |
Income Statement
| Revenue (ttm) | 1.2M USD |
| Revenue Per Share (ttm) | 0.04 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | 1.2M USD |
| EBITDA | -46548000 USD |
| Net Income Avi to Common (ttm) | -29799000 USD |
| Diluted EPS (ttm) | -0.98 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 15.85M USD |
| Total Cash Per Share (mrq) | 0.47 USD |
| Total Debt (mrq) | 25.67M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 0.883 |
| Book Value Per Share (mrq) | -0.091 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -34243000 USD |
| Levered Free Cash Flow (ttm) | -15498125 USD |
Profile of Rani Therapeutics
| Country | United States |
| State | CA |
| City | San Jose |
| Address | 2051 Ringwood Avenue |
| ZIP | 95131 |
| Phone | 408 457 3700 |
| Website | https://www.ranitherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 105 |
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-116 which is in discovery stage for the treatment of obesity; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
Q&A For Rani Therapeutics Stock
What is a current RANI stock price?
Rani Therapeutics RANI stock price today per share is 1.48 USD.
How to purchase Rani Therapeutics stock?
You can buy RANI shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Rani Therapeutics?
The stock symbol or ticker of Rani Therapeutics is RANI.
Which industry does the Rani Therapeutics company belong to?
The Rani Therapeutics industry is Biotechnology.
How many shares does Rani Therapeutics have in circulation?
The max supply of Rani Therapeutics shares is 122.65M.
What is Rani Therapeutics Price to Earnings Ratio (PE Ratio)?
Rani Therapeutics PE Ratio is now.
What was Rani Therapeutics earnings per share over the trailing 12 months (TTM)?
Rani Therapeutics EPS is -0.77 USD over the trailing 12 months.
Which sector does the Rani Therapeutics company belong to?
The Rani Therapeutics sector is Healthcare.
Rani Therapeutics RANI included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 23613.31 USD — |
+0.22
|
3.54B USD — | 23527.97 USD — | 23621.72 USD — | — - | 3.54B USD — |
| US Tech Global Market Composite NQGM | 2346.16 USD — |
+0.86
|
— — | 2326.43 USD — | 2347.01 USD — | — - | — — |
| US Tech Biotechnology NBI | 5843.74 USD — |
+0.69
|
— — | 5812.05 USD — | 5851.25 USD — | — - | — — |
| US Tech Health Care IXHC | 1212.11 USD — |
+0.55
|
— — | 1206.25 USD — | 1213.6 USD — | — - | — — |
| Stlmt ID US Tech Biotechnology NBX | 3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}